<DOC>
	<DOCNO>NCT00794313</DOCNO>
	<brief_summary>Levodopa main drug treatment Parkinson 's disease . Levodopa cause unwanted uncontrolled movement call dyskinesia . A drug call amantadine reduce movement . To date , objective measure movement . The purpose study measure reduction movement amantadine and/or topiramate use objective measure .</brief_summary>
	<brief_title>Quantification Antidyskinetic Effect Amantadine Topiramate Parkinson 's Disease</brief_title>
	<detailed_description>Nearly Parkinson 's disease ( PD ) patient eventually develop abnormal unwanted movement ( dyskinesia ) cause gold standard treatment , Levodopa . The severity movement range subtle extremely debilitate may may interfere normal activity put coat brush one teeth . Currently , one treatment unwanted involuntary movement Amantadine . New option treat dyskinesia would clinically valuable . In previous study , develop objective measuring device quantify dyskinesia . All PD participant receive three drug treatment intervention ( placebo , Amantadine 300 mg , Amantadine 300 mg plus Topiramate 150 mg ) . After 2 week one drug treatment , participant complete overnight visit OCTRI Inpatient unit . During next day , participant complete mental task stand force plate one minute every half hour end study . A levodopa IV infusion occur 0900 1100 . The subject split 'high ' 'low ' dose group . Those take &lt; 50 mg/hour oral levodopa levodopa equivalent consider 'low ' dose subject receive 1 mg/kg/hr IV Levodopa study visit ( 1 , 2 , 3 ) . Those administer &gt; 50 mg/hr oral levodopa normally consider 'high ' dose subject receive 1.5 mg/kg/hr levodopa . Both group receive infusion two hour 0900 - 1100 . The study drug take orally 0800 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Parkinson 's Disease At least 21 year age Must take Oral levodopa Must dyskinesias history previous clinical observation Significant cognitive impairment measure Montreal Cognitive Assessment ( MOCA ) score &lt; 25 Subjects unstable medical psychiatric condition ( include hallucination ) Use dopamine receptor block medication ( e.g. , neuroleptic , certain antiemetic , tetrabenazine ) History unstable medical condition ( ie active cardiovascular disease , recent unwellness surgery etc . ) Use anticoagulant Current substance abuse Previous adverse event amantadine</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Parkinsons disease</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>amantadine</keyword>
	<keyword>efficacy</keyword>
</DOC>